Fresenius Kabi, Samsung Bioepis lock horns again over Humira biosimilar
Intellectual Property 2022-09-13 10:30 pm By Cindy Cameronne | Sydney
Please login to bookmark Close

German biotech Fresenius Kabi has struck back at Samsung Bioepis’s latest attack on the validity of its patents for a liquid formulation of top selling immunosuppressant drug Humira, accusing the Korean company of causing its sales to flag by infringing the patent.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au